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The SecYEG complex constitutes a protein conducting
channel across the bacterial cytoplasmic membrane. It
binds the peripheral ATPase SecA to form the translo-
case. When isoleucine 278 in transmembrane segment 7
of the SecY subunit was replaced by a unique cysteine,
SecYEG supported an increased preprotein transloca-
tion and SecA translocation ATPase activity, and al-
lowed translocation of a preprotein with a defective
signal sequence. SecY(I278C)EG binds SecA with a
higher affinity than normal SecYEG, in particular in the
presence of ATP. The increased translocation activity of
SecY(I278C)EG was confirmed in a purified system con-
sisting of SecYEG proteoliposomes, while immunopre-
cipitation in detergent solution reveal that translocase-
preprotein complexes are more stable with SecY(I278C)
than with normal SecY. These data imply an important
role for SecY transmembrane segment 7 in SecA binding.
As improved SecA binding to SecY was also observed
with the prlA4 suppressor mutation, it may be a general
mechanism underlying signal sequence suppression.
The components of the bacterial protein secretion pathway
have originally been identified in Escherichia coli through both
genetic (1, 2) and biochemical studies (3). The translocation
reaction across the cytoplasmic membrane is mediated by an
enzyme complex termed the translocase. The translocase ho-
loenzyme is an assembly of integral membrane proteins,
termed SecY (or PrlA) and SecE (PrlG), together with a periph-
eral ATPase termed SecA (PrlD). The SecYE complex is homo-
logues to the eukaryotic Sec61p complex of the endoplasmic
reticulum membrane (4) and both complexes appear to consti-
tute a transmembrane protein conducting channel (5–7). The
SecA protein is unique for bacteria, and for organelles evolu-
tionary derived thereof (8). During cycles of ATP binding and
hydrolysis SecA supports a stepwise translocation reaction (9,
10), coupled to cycles of membrane insertion and deinsertion at
SecYE (11). An additional source of energy for the translocation
reaction is the proton-motive force. The proton-motive force
positively affects the unidirectionality of the translocation re-
action (12), possibly by directly driving the translocation of
preproteins in the absence of SecA (9) as well as by stimulating
the SecA reaction cycle (13). Other proteinaceous factors in-
volved in the translocation reaction are SecG (PrlH) (14) and a
trimeric complex consisting of the SecD, SecF, and YajC pro-
teins (15). SecG inverts its membrane topology concomitantly
with the membrane cycling of SecA (16), whereas SecDFYajC
stabilizes the membrane inserted state of SecA (17, 18). Both
SecG and the SecDFYajC complex interact with the SecYE
complex and stimulate translocation (15). For the efficient in
vitro reconstitution of preprotein translocation, SecYEG is used
as it is readily purified as a detergent-solubilized complex (19,
20). Stimulation of the translocation reaction by SecG has been
demonstrated using the purified and reconstituted translocase
(14, 21). Reconstituted SecYEG allows multiple rounds of
translocation (22) as well as the integration of transmembrane
segments into the lipid bilayer (23).
Genetic studies have identified mutations in translocase
components that allow the correct cellular localization of pre-
proteins carrying a defective signal sequence (24–28). How
these prl mutations (for protein localization) suppress defective
signal sequence recognition is yet unclear, but a direct resto-
ration of the interaction between translocase and the signal
sequence is unlikely. First, the number of prl alleles is too large
to account for a single recognition event. Second, even (pre)pro-
teins that lack the complete signal sequence are transported in
strains carrying prlA (secY) or prlG (secE) suppressor muta-
tions (29, 30). Alternatively, prl suppressor mutations may
alter important enzymological events underlying the translo-
cation reaction. Allele-specific synthetic lethality caused by
combinations of prlA and prlG suppressor mutations suggest
that they affect subunit interactions between SecY and SecE
(31). Recently, it was shown that the prlA4 suppressor muta-
tion supports increased binding of SecA to translocation sites in
the cytoplasmic membrane (32). This increased affinity for
SecA leads to a decreased rejection of SecA or SecA-precursor
complexes during translocation. Finally, prlA suppressors alter
the translocation reaction less dependent on the proton-motive
force (33).
In an effort to understand the nature and the dynamics of
subunit interactions within the translocase, we employed cys-
teine-scanning mutagenesis to regions of SecY and SecE that
contain, or are proximal to, clusters of prl suppressor muta-
tions. Cysteine scanning mutagenesis has been used as a pow-
erful technique to study structure-function relationships in
membrane proteins, including the E. coli lactose permease
LacY (34) and the eukaryotic multidrug transporter P-glyco-
protein (35, 36). SecY contains prlA suppressor mutations that
cluster mainly in transmembrane segment (TMS)1 2, TMS 7,
and TMS 10, and in periplasmic loop 1 (P1) (37). Synthetic
lethality between prlG and prlA suppressor mutations suggests
interactions of SecE TMS 3 with SecY TMS 7 and 10, and
between SecY P1 and SecE P2 (31). The replacement of consec-
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utive residues by cysteines in SecY TMS 2 and SecE TMS 3
identified contacts at specific helical interfaces between these
two protein regions and between neighboring SecE molecules
(38). The latter interaction is dynamic and is modulated by
conformational changes in the SecA protein. We now report on
the cysteine mutagenesis of SecY TMS 7, which yielded a SecY
molecule that supports increased translocation ATPase activ-
ity. This mutant possesses a unique cysteine at the position of
isoleucine 278, a residue that is altered by several prlA sup-
pressor mutations. Inner membrane vesicles (IMVs) or proteo-
liposomes containing SecY(I278C)EG not only supported in-
creased translocation of normal preproteins, but also allowed
translocation of a preprotein carrying a defective signal se-
quence. Binding studies further demonstrated that, like the
PrlA4 suppressor, SecY(I278C) has a higher affinity for SecA
than normal SecY. The latter permits efficient co-immunopre-
cipitation of translocase-preprotein complexes even without
prior stabilization by a preprotein translocation intermediate.
The data suggest an important role for SecY TMS 7 in SecA
binding and support a model in which stabilization of the
SecA-SecY interaction leads to increased translocation of nor-
mal preproteins concomitant with a reduced rejection of pre-
proteins with a defective signal sequence.
EXPERIMENTAL PROCEDURES
Materials—Monoclonal antibodies against OmpA were raised and
selected by Prof. Dr. L. de Leij, Academic Hospital Groningen. Poly-
clonal antisera against purified SecY or SecA were obtained as de-
scribed (20). Western blots were developed as films using chemilumi-
nescence (Tropix, Bedford, MA). For densitometry a Dextra DF-2400T
scanner (Dextra Technology Corp., Taipei, Taiwan) and SigmaScan/
Image Software (Jandel Corp., San Rafael, CA) were used. DNA se-
quence analysis was performed on a Vistra DNA sequencer 725 using
the automated Dtaq sequencing kit (Amersham Pharmacia Biotech,
Buckinghamshire, United Kingdom). Protein A-Sepharose was from
Amersham Pharmacia Biotech (Uppsala, Sweden), n-octyl-b-D-glucopy-
ranoside (octyl glucoside) from Sigma, and E. coli phospholipids from
Avanti Polar Lipids Inc. (Alabaster, AL).
Plasmids—All plasmids used for this study are described in Table I.
The construction of plasmids that allow the overexpression of SecYEG,
(His)6-tagged SecYEG (20), or cysteine-less SecYEG (38) has been de-
scribed previously. Cysteines were introduced in SecY TMS 7 by a
two-step polymerase chain reaction mutagenesis. To facilitate the
screening for correct mutants, cysteine mutagenesis was accompanied
by the GGT 3 GGA (G350G) mutation, leading to the insertion of a
BspEI restriction site. An amino-terminal (His)6-tag on SecY(I278C)
was obtained by cloning the NcoI/BamHI fragment from pET615 (Table
I) into NcoI/BamHI-digested pET302 (20). All constructs were con-
firmed by sequence analysis.
Translocation Reactions—(His)6-tagged SecYEG was purified and
reconstituted into proteoliposomes as described (20), and other compo-
nents of the translocation reaction were obtained as in Ref. 32. Concen-
trations of the different components are mentioned in the text or figure
legends. Reactions were incubated at 37 °C in a total volume of 100 ml
of translocation buffer (50 mM Hepes-KOH, pH 7.6, 50 mM KCl, 5 mM
MgCl2, 0.5 mg/ml bovine serum albumin, and 10 mM dithiothreitol) and
stopped by chilling on ice and protease K treatment (10).
Immunoprecipitation—Proteoliposomes from two translocation reac-
tions were collected by centrifugation (20 min, 120,000 3 g), and solu-
bilized in buffer C (1.25% (w/v) octyl glucoside, 0.3 mg/ml E. coli phos-
pholipids, 20% (v/v) glycerol, 50 mM KCl and 50 mM Tris-HCl, pH 8.0)
for 1 h on ice. Protein A-Sepharose slurry (10 ml) was incubated with 20
ml of antiserum diluted in 200 ml of buffer A for 1 h at 4 °C, washed, and
mixed with the solubilized proteoliposomes. After 90 min of constant
shaking at 4 °C, Sepharose beads were collected (3 min, 12,000 3 g) and
washed five times with 0.3 ml of buffer C. Bound proteins were eluted
by incubation with 60 ml of SDS sample buffer for 10 min at 60 °C and
separated from the Sepharose beads by centrifugation.
RESULTS
Identification of a Mutation in SecY That Supports Increased
Translocation—As part of a larger cysteine-scanning mutagen-
esis study (38), unique cysteine residues were introduced in
TMS 7 of SecY. To cover at least two turns of the putative
a-helical structure, 8 residues in TMS 7 (Val274-Ser281) were
mutagenized to cysteine residues (Fig. 1). Substitutions of two
of these residues that face the same side of the helix, Val274 and
Ile278, have been reported to give rise to suppressor phenotypes
(37). The mutant secY genes were cloned in pET602, a vector
that allows overexpression of cysteine-less SecYEG, which is
functionally indistinguishable from normal SecYEG (38). Al-
though the expression of SecYEG was similar with all TMS 7
mutants (Fig. 2A), there was a pronounced increase in SecA
ATPase activity with SecY(I278C)EG IMVs (Fig. 2B). More-
over, this resulted in increased translocation of the preprotein
proOmpA (Fig. 2C). To test whether the increased activity of
the SecY(I278C)EG complex affected its specificity, we exam-
ined the translocation of D8proOmpA, a variant precursor car-
rying a defective signal sequence due to the deletion of Ile8 (41)
that is efficiently translocated by PrlA4 IMVs (32). This pre-
cursor was transported only into the SecY(I278C)EG IMVs
(Fig. 2D), demonstrating that the I278C mutation causes a loss
of specificity for the signal sequence. Apparently, the introduc-
tion of cysteines at the other positions of SecY TMS 7, including
Val274, did not alter the activity or specificity of translocase.
Increased SecA Binding to SecY(I278C)EG—With the PrlA4
suppressor, which contains the F286Y substitution in TMS 7
and I408N in TMS 10, an increased affinity for SecA was
observed as compared with normal PrlA (SecY). The difference
in SecA binding is even larger upon the addition of ATP, which
TABLE I
Plasmids
A synthetic secYEG operon behind the isopropyl-b-D-thiogalactoside-inducible trc promoter was used for the plasmid-derived overexpression of
the SecYEG complex. All plasmids encoding single cysteine SecYEG were constructed via polymerase chain reaction mutagenesis, resulting in the
indicated mutations.
Plasmid Relevant characteristics Mutations Source
pET340 SecYEG tandem behind trc promotor Ref. 20
pET349 His-tagged SecYEG in pET340 Ref. 20
pET602 Cysteine-less YEG in pET605 Ref. 38
pET605 pET340 with DHincII in secE L60L (CTG-.CTC) Ref. 38
pET607 Cysteine-less YEG in pET610 Ref. 38
pET610 pET349 with DHincII in SecE L60L (CTG-.CTC) Ref. 38
pET611 SecY TMS7 mutant 1 in pET602 V274C (GTA-.TGT) G350G (GGT-.GGA) This study
pET612 SecY TMS7 mutant 2 in pET602 I275C (ATC-.TGC) G350G (GGT-.GGA) This study
pET613 SecY TMS7 mutant 3 in pET602 P276C (CCG-.TGT) G350G (GGT-.GGA) This study
pET614 SecY TMS7 mutant 4 in pET602 A277C (GCA-.TGT) G350G (GGT-.GGA) This study
pET615 SecY TMS7 mutant 5 in pET602 I278C (ATC-.TGC) G350G (GGT-.GGA) This study
pET616 SecY TMS7 mutant 6 in pET602 F279C (TTC-.TGC) G350G (GGT-.GGA) This study
pET617 SecY TMS7 mutant 7 in pET602 A280C (GCT-.TGT) G350G (GGT-.GGA) This study
pET618 SecY TMS7 mutant 8 in pET602 S281C (TCC-.TGC) G350G (GGT-.GGA) This study
pET650 His-tagged SecY TMS7 mutant 5 in pET340 This study
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lowers the affinity, but to a much lesser extent with PrlA4 (32).
Since SecY(I278C) allows translocation of D8proOmpA, we
compared the binding of SecA to IMVs containing overproduced
SecYEG, cysteine-less SecYEG or SecY(I278C)EG (Fig. 3). As
expected from their similar activity (Fig. 2), the binding of SecA
to SecYEG or cysteine-less SecYEG was nearly identical (Fig.
3A, closed bars) and was reduced to the same level in the
presence of ATP (open bars). In contrast, the binding of SecA to
SecY(I278C)EG IMVs was significantly higher and was only
slightly reduced in the presence of ATP. Using a concentration
range of SecA, we determined the affinity of SecA binding to
the IMVs containing cysteine-less SecYEG (Fig. 3B) or
SecY(I278C)EG (Fig. 3C) by Scatchard analysis (42). IMVs
contained 2.1–2.4 mM/mg high affinity SecA-binding sites, a
25–30-fold increase as compared with IMVs harboring endog-
enous levels of SecYEG (80 nM/mg; Ref. 32). SecA binds to
overproduced cysteine-less SecYEG with a Kd of 4 nM in the
absence and a Kd of 16 nM in the presence of ATP. These
affinities are somewhat higher, but comparable, to those ob-
served with endogenous SecYEG, i.e. 7 nM without and 24 nM
with ATP (32), and confirm that SecYEG is functionally over-
expressed. Compared with cysteine-less SecYEG, the affinity of
SecA binding to SecY(I278C)EG was 2.5-fold higher in the
absence of ATP (Kd 5 1.6 nM) and 5.7-fold higher in the pres-
ence of ATP (Kd 5 2.8 nM). These data demonstrate that the
SecY(I278C) mutation results in an increased affinity of the
SecYEG complex for SecA, especially in the presence of ATP.
With PrlA4, SecA binding occurs with a Kd of 1.4 nM in the
absence and a Kd of 3.6 in the presence of ATP. The increased
affinity leads to a decreased rejection of SecA-precursor com-
plexes, and less dissociation of SecA during translocation (32).
We propose that the same phenomenon is responsible for the
increased translocation activity and lowered specificity of
SecY(I278C).
Translocation Activity of Purified SecY(I278C)EG—To study
the translocation activity of the purified SecY(I278C)EG com-
plex, a (His)6-tag was positioned at the amino terminus of SecY.
The complex was then overexpressed, purified, and reconsti-
tuted as described previously (20). (His)6SecY(I278C)EG pro-
teoliposomes were compared with those reconstituted with the
same amount of normal (His)6SecYEG. As observed with IMVs,
the proOmpA-stimulated ATPase activity was highest with
SecY(I278C)EG proteoliposomes (Fig. 4A, closed bars). How-
ever, when D8proOmpA was used in the translocation reaction,
hardly any stimulation of the SecA translocation ATPase ac-
tivity was observed (Fig. 4A). Therefore, the amounts of trans-
located precursor were visualized by Western blotting using
monoclonal antibodies against OmpA. Quantitative analysis of
these blots demonstrated that after 20 min only a minor frac-
tion (,0.5%) of the D8proOmpA was translocated in
SecY(I278)EG proteoliposomes, as compared with normal
proOmpA (about 25%) (Fig. 4, B and C, closed symbols). To
demonstrate that the translocated protein was truly
D8proOmpA, and not the result of an impurity with endoge-
FIG. 1. Localization of unique cysteines in SecY and SecE. Amino acids were replaced by cysteines (black circles) in SecY TMS 7 using a
cysteine-less SecYEG background. SecE and SecG are devoid of cysteines and the two endogenous cysteines of SecY (black diamonds) were replaced
by serine residues (38). Positions of the replaced residues are based upon topology models of SecY (39, 40). The position of the I278C substitution
in SecY TMS 7 is marked with an asterisk.
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nous proOmpA from the host strain used for purification, we
repeated the experiment with in vitro synthesized and purified
[35S]methionine-labeled D8proOmpA (Fig. 4D). This clearly
showed that purified SecY(I278C)EG allows the translocation
of this defective precursor. The sensitivity of the autoradio-
grams (Fig. 4D) was somewhat higher than that obtained by
Western blots (Fig. 4C) and revealed a minimal level of
D8proOmpA translocation with normal SecYEG, confirming in
vivo data (41).
In the absence of reducing agents, proOmpA is blocked for
further translocation at the position of a disulfide-bond be-
tween two unique cysteine residues (Cys290 and Cys302) in its
carboxyl terminus (9, 43). In proteoliposomes, this results in
the accumulation of a 31-kDa translocation intermediate (I31)
(Fig. 4E). This intermediate occupies the translocation sites
and blocks them for a second round of translocation (Ref. 22
and data not shown). With the normal proteoliposomes, maxi-
mal I31 translocation was reached after 10 min, whereas pro-
teoliposomes with SecY(I278C) accumulated maximal amounts
within the first 5 min of the translocation reaction (Fig. 4E).
SecY(I278C) did not allow the full-length translocation of oxi-
dized proOmpA and thus differs in this respect from PrlA4
(33). The fast kinetics of the translocation reaction with
SecY(I278C), as compared with normal SecY, is apparent from
the initial rate of translocation (Fig. 4B) and the shorter time
required to saturate the translocation sites with I31 (Fig. 4E).
The experiments with proteoliposomes demonstrate that the
SecY(I278C) mutation stimulates SecA- and ATP-driven trans-
location, and that this effect does not require proteinaceous
factors other than the SecYEG complex. In addition,
FIG. 2. Overexpression and activity of the SecY TMS 7 cysteine
mutants. A, isolated IMVs containing overexpressed normal SecYEG
(lane 1), cysteine-less SecYEG (lane 2), or SecYEG with unique cys-
teines at positions 274–281 of SecY TMS 7 (lanes 3–10) were analyzed
by SDS-PAGE and Coomassie Brilliant Blue staining. B, SecA ATPase
activity in the presence of urea-treated IMVs was measured in the
absence (open bars) and presence (black bars) of proOmpA, as described
previously (20). Data represent the average of two experiments, IMVs
are numbered as in A. C, translocation of [35S]methionine-labeled
proOmpA with urea-treated IMVs (20 mg/ml) in the presence of SecA
(10 mg/ml) and ATP (2 mM). Reactions (50 ml) were stopped after 20 min
by chilling on ice and protease K treatment, yielding protease-protected
proOmpA which is partially processed to OmpA by endogenous leader
peptidase. D, translocation of [35S]methionine-labeled D8proOmpA,
carrying a defective signal sequence using the conditions described
under C.
FIG. 3. Increased SecA binding to SecY(I278C)EG. A, SecA bind-
ing to IMVs containing overexpressed SecYEG (WT), cysteine-less
SecYEG (Cys-less), or SecY(I278C)EG (I278C). Binding was determined
using 125I-labeled SecA (2 mg/ml) and urea-treated IMVs (10 mg/ml) in
the absence (filled bars) and presence (open bars) of 2 mM ATP. B,
Scatchard analysis of SecA binding (1–200 nM) to urea-treated IMVs (10
mg/ml) containing overexpressed cysteine-less SecYEG in the absence
(closed circles) and presence (open circles) of 2 mM ATP. C, same as B,
with IMVs containing overexpressed SecY(I278C)EG. All binding ex-
periments were performed as described previously (32, 47). As no de-
tectable background binding of SecA was observed, uncorrected data
are shown.
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SecY(I278C) enforces the translocation of D8proOmpA with
purified translocase.
SecY(I278C) Stabilizes Translocase-Precursor Complexes—
Co-immunoprecipitation was used to assay the stability of
translocase-precursor complexes formed during ongoing trans-
location or at halted stages of the translocation reaction. Pro-
teoliposomes were incubated with SecA and proOmpA in the
absence of ATP (targeting of SecA and the precursor), the
presence of ATP (ongoing translocation), or with ATP under
oxidizing conditions (blocked translocation, yielding I31). The
proteoliposomes were then harvested by centrifugation and
solubilized in the detergent octyl glucoside. Samples were im-
munoprecipitated with polyclonal antiserum against SecA or
SecY, and co-precipitation of proOmpA was visualized by im-
munoblotting using a monoclonal antibody against OmpA (Fig.
5A). No, or only very little, interaction between proOmpA and
either SecY or SecA was observed with normal translocase
after incubation in the absence of ATP (lanes 1 and 7). After
translocation under reducing conditions, a fraction of proOmpA
was associated with SecY but not with SecA (lanes 2 and 8).
Apparently, SecA has dissociated from these SecYEG-precur-
sor complexes. Only after translocation of I31, fully stable
translocase-precursor complexes were formed (lanes 3 and 9).
In contrast, SecY(I278C) translocase-precursor complexes were
precipitated independent of the preincubation (lanes 4–6 and
10–12). Only immunoprecipitation with anti-SecYE serum
yielded a significantly lowered amount of proOmpA after incu-
bation in the absence of ATP (lane 4). Antibodies against SecY
interfere with SecA binding (44, 45) and therefore may desta-
bilize translocase. In conclusion, SecY(I278C) translocase-pre-
cursor complexes are more stable than their counterparts con-
taining normal SecY. Wild-type translocase is, however,
stabilized by the I31 translocation intermediate. This is consist-
ent with experiments in IMVs that suggest a stable association
of this intermediate with SecA at translocation sites (9).
FIG. 5. Co-immunoprecipitation of proOmpA with translocase.
SecYEG (lanes 1–3 and 7–9) or SecY(I278C)EG (lanes 4–6 and 10–12)
proteoliposomes were incubated for 20 min with proOmpA and 2 mM
ATP and/or 10 mM dithiothreitol, as indicated. After solubilization of
the proteoliposomes with octyl glucoside, samples were immunoprecipi-
tated with antibody against SecY (lanes 1–6) or SecA (lanes 7–12).
Co-precipitation of proOmpA was analyzed by immunoblotting using a
monoclonal antibody against OmpA.
FIG. 4. SecY(I278C) increases the activity of the translocase. A, ATPase activities of 20 mg/ml SecA was measured after 20 min of
incubation with 2 mM ATP and 4 mg/ml reconstituted purified SecYEG (open bars) or SecY(I278C)EG (closed bars) (4–6 ml of proteoliposomes), in
the absence (2) or presence (1) of 10 mg/ml proOmpA or D8proOmpA (D8). B, translocation of proOmpA with reconstituted SecYEG (open circles)
or SecY(I278C)EG (closed circles) was performed as in A, and stopped at the indicated times by chilling on ice and protease K treatment.
Protease-protected proOmpA was visualized by immunoblotting using a monoclonal antibody against OmpA and quantitated by densitometrical
analysis of films from chemiluminescent blots. C, same as B, with D8proOmpA. D, translocation of [35S]methionine-labeled D8proOmpA into
proteoliposomes containing SecYEG (lanes 1–4) or SecY(I278C)EG (lanes 5–8). E, immunoblot of protease-protected proOmpA after translocation
in the absence of reducing agents, with SecYEG (lanes 1–4) or SecY(I278C)EG proteoliposomes. A disulfide bond between Cys290 and Cys302 in
proOmpA results in the accumulation of translocation intermediate I31.
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The E. coli translocase is composed of the SecA ATPase
bound to a transmembrane protein conducting channel with
SecY and SecE as core components (19), and with SecG as an
additional subunit (14, 21). The identification and reconstitu-
tion of its minimal constituents (19–21) have made translocase
an intriguing model to study subunit dynamics in a membrane
protein complex. To allow site-directed labeling of functionally
important regions in translocase and to detect specific inter-
molecular contacts, we have employed cysteine mutagenesis of
regions in SecY and SecE that contain clusters of prlA or prlG
suppressor mutations, respectively (31, 37, 38). From the single
cysteine mutants at positions 274–281 of SecY TMS 7, the
I278C substitution resulted in an increased translocation ac-
tivity and gave rise to in vitro defective signal sequence sup-
pression, as measured by the translocation of D8proOmpA.
Previously, prlA suppressor mutations have been identified
that lead to substitutions of I278 for Ser (prlA202, 203, 204,
and 207), Asn (prlA208), or Thr (prlA303) residues (37). It thus
seems that Ile278 is a hot spot for such suppressor mutations.
SecY(V274C) did not alter the activity and specificity of trans-
locase, although prlA suppressor mutations have been identi-
fied that result in a V274G substitution (prlA1, 2, 5 and 201;
Ref. 37). Apparently, the amino acid substitutions that give rise
to prl suppression depend not only on the position but also on
the nature of the substituted amino acid. We have also con-
structed plasmids that allowed co-overexpression of the SecY
mutants with cysteines at positions 105–109 of SecE TMS 3.
Although synthetic lethality was observed between prlA208
(I278N) and prlG1 (L108R) (31), none of the combined mutants
yielded cross-links between SecY and SecE upon oxidation
(data not shown). This implies that synthetic lethality does not
necessarily result from a direct interaction between two amino
acids.
One of the earliest identified prlA suppressor mutations is
prlA4 (24). Its suppressor phenotype is caused by the I408N
substitution in SecY TMS 10, but this mutation is generally
accompanied by the F286Y substitution in TMS 7 or, with
prlA6, S188L in TMS 5 (37, 46, 47). The apparently unavoid-
able occurrence of secondary mutations may reflect a detrimen-
tal effect of the I408N substitution on the E. coli cell. SecA
binds to PrlA4 with an increased affinity, and this results in a
decreased rejection of SecA and the preprotein at the onset of
translocation (32). We now report on a similar phenomenon
with SecY carrying the I278C amino acid substitution in TMS
7 in a cysteine-less background. This mutant supports an in-
creased translocase activity and translocates D8proOmpA, car-
rying a defective signal sequence. As the activity of cysteine-
less SecYEG is indistinguishable from normal SecYEG (this
study and Ref. 38), the I278C mutation appears solely respon-
sible for the observed phenotype (see Fig. 2D). Using affinity
blotting, the amino-terminal half of SecY was detected as a
binding site for SecA (48). The increased affinity for SecA
caused by this I278C substitution, however, indicates that
SecY TMS 7 also serves as a site of interaction with SecA.
Alternatively, this mutation affects binding of SecA to the
amino-terminal half of SecY. Our data support a model in
which prlA suppression is the result of improved binding be-
tween SecA and SecY. This will optimize the translocation of
normal preproteins due to a better targeting of SecA to SecYEG
and less dissociation of the translocase components during
ATP-driven translocation. At the same time, it lowers the
proofreading activity of translocase as SecA carrying a defec-
tive preprotein is less easily rejected from translocation sites at
the onset of translocation, likely upon the binding of ATP. Since
proton-motive force-driven translocation is prevented by the
presence of SecA (9), an increased affinity for SecA may explain
why PrlA suppressors render the translocation reaction proton-
motive force-independent (33).
The stabilization of translocase-precursor complexes by
SecY(I278C) during translocation was directly demonstrated
by co-immunoprecipitation. With normal SecY, a soluble trans-
locase-precursor complex required the presence of a stable
translocation intermediate I31. No complexes between SecA or
SecY with the precursor were observed after incubation in the
absence of ATP, and SecA readily dissociated from the complex
during an ongoing translocation reaction. With SecY(I278),
translocase-preprotein complexes were completely stable after
incubation under translocating conditions, as compared with
complexes with trapped I31. Incubation in the absence of ATP
yielded complexes that were susceptible for dissociation by an
antibody against SecY. This suggests that the SecYEG channel
alters its conformation during translocation, rendering the in-
teraction with SecA and the preprotein more stable. This con-
formational change may involve subunit rearrangements, or
channel “opening,” as has been observed with the Sec61p com-
plex during translocation (49, 50).
Whereas increased SecA binding is a clear phenotype of both
PrlA4 and SecY(I278C), they are functionally different in two
aspects. First, PrlA4 allows translocation of a disulfide bonded
loop of 10 amino acids in the mature region of proOmpA (33),
whereas SecY(I278C) does not (Fig. 4E). Second, PrlA4 sup-
ports increased translocation with a lowered SecA ATPase
activity (32), whereas with SecY(I278C), the increased trans-
location is accompanied by a concomitant increase in the rate of
ATP hydrolysis by SecA. The affinity of PrlA4 and SecY(I278C)
for SecA is hardly different and we therefore hypothesize that
PrlA4 and SecY(I278C) differ mechanistically. Suppressor mu-
tations in SecY TMS 10 appear to strongly affect the interac-
tion with SecE TMS 3 (31, 37). As conformational changes in
SecE TMS 3 and SecA membrane cycling are interrelated (38),
the I408N mutation in PrlA4 may slow the SecA reaction cycle
due to an altered interaction with SecE. A slowed ATPase
activity has been proposed as a mechanism for prlD (secA)
suppression by increasing the lifetime of SecA-preprotein com-
plexes during translocation (27). With PrlA4, improved SecA
binding to the SecYEG complex at the same time makes trans-
location highly efficient. We propose that SecY(I278C) is a
milder suppressor than PrlA4 because it does not affect the
SecA reaction cycle. Extensive biochemical analysis of other
Prl suppressors will unravel more of the mechanistic aspects
underlying signal sequence recognition and the activity of
translocase.
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